The effect of the PI3K inhibitor BKM120 on tumour growth and osteolytic bone disease in multiple myeloma

Highlights • BKM120 decreases MM cell proliferation in vitro and MM tumour burden in vivo. • BKM120 reduces the incidence of osteolytic bone lesions in vivo. • BKM120 inhibits osteoclast formation and stimulates osteoblast function in vitro. • BKM120 is an attractive new MM therapy.

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Leukemia research 2015-03, Vol.39 (3), p.380-387
Hauptverfasser:	Martin, Sally K, Gan, Zhen Ying, Fitter, Stephen, To, Luen B, Zannettino, Andrew C.W
Format:	Artikel
Sprache:	eng
Schlagworte:	Aminopyridines - pharmacology Animals Apoptosis - drug effects BKM120 Blotting, Western Bone Bone Diseases - drug therapy Bone Diseases - metabolism Bone Diseases - pathology Cell Cycle - drug effects Cell Proliferation - drug effects Disease Models, Animal Enzyme Inhibitors - pharmacology Enzyme-Linked Immunosorbent Assay Hematology, Oncology and Palliative Medicine Humans Mice Mice, Inbred C57BL Morpholines - pharmacology Multiple myeloma Multiple Myeloma - drug therapy Multiple Myeloma - metabolism Multiple Myeloma - pathology Osteoclasts - cytology Osteoclasts - drug effects Osteoclasts - metabolism Osteolysis - drug therapy Osteolysis - metabolism Osteolysis - pathology Phosphatidylinositol 3-Kinases - antagonists & inhibitors PI3K Tumor Burden Tumor Cells, Cultured Xenograft Model Antitumor Assays
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Highlights • BKM120 decreases MM cell proliferation in vitro and MM tumour burden in vivo. • BKM120 reduces the incidence of osteolytic bone lesions in vivo. • BKM120 inhibits osteoclast formation and stimulates osteoblast function in vitro. • BKM120 is an attractive new MM therapy.
ISSN:	0145-2126 1873-5835
DOI:	10.1016/j.leukres.2014.12.015